BioNTech's SWOT analysis: oncology pipeline, cash boost stock outlook
BioNTech SE (NASDAQ:BNTX), a biotechnology company renowned for its mRNA technology platform and COVID-19 vaccine success, is navigating a crucial phase in its evolution. With a market capitalization ...
HHS Secretary nominee RFK Jr. faces contentious Senate hearing
Senate confirmation hearing for HHS Secretary nominee Robert Kennedy Jr. turns contentious as Democratic lawmakers press him ...
Vaccine stocks in focus as RFK Jr. faces confirmation hearing
Leading vaccine makers are under investor scrutiny as Robert F. Kennedy Jr., a notable vaccine skeptic and President Donald Trump’s nominee to lead the Department of Health and Human Services (HHS), ...
Peering Into BioNTech's Recent Short Interest
According to Benzinga Pro, BioNTech's peer group average for short interest as a percentage of float is 5.26%, which means ...
Here's How to Play Pfizer Stock Before Q4 Earnings Release
PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the ...
BioNTech SE (BNTX) Receives a Hold from J.P. Morgan
In a report released today, Jessica Fye from J.P. Morgan maintained a Hold rating on BioNTech SE (BNTX – Research Report), with a price target ...
Morgan Stanley Sticks to Their Buy Rating for BioNTech SE (BNTX)
Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $145.00.
BioNTech SE (NASDAQ:BNTX) Position Increased by Atomi Financial Group Inc.
Atomi Financial Group Inc. raised its stake in BioNTech SE (NASDAQ:BNTX – Free Report) by 6.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional ...